Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRME Prime Medicine, Inc.

Not Yet Opened 09-24 16:00:00 EDT

3.07

-0.06

-1.92%

盘后3.43

+0.36+11.73%

19:59 EDT

High3.13	Low2.99	Vol4.49M
Open3.11	D1 Closing3.13	Amplitude4.47%
Mkt Cap554.17M	Tradable Cap356.12M	Total Shares180.51M
T/O14.14M	T/O Rate3.87%	Tradable Shares116.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRME","market":"US","secType":"STK","nameCN":"Prime Medicine, Inc.","latestPrice":3.07,"timestamp":1790280000000,"preClose":3.13,"halted":0,"volume":4485368,"hourTrading":{"tag":"盘后","latestPrice":3.4301,"preClose":3.07,"latestTime":"19:59 EDT","volume":1896151,"amount":6531260.1016,"timestamp":1790294399645,"change":0.3601,"changeRate":0.117296,"amplitude":0.172638},"delay":0,"changeRate":-0.019169329073482445,"floatShares":115999999,"shares":180510658,"eps":-1.085332,"marketStatus":"Not Yet Opened","change":-0.06,"latestTime":"09-24 16:00:00 EDT","open":3.11,"high":3.13,"low":2.9901,"amount":14143851.3064184,"amplitude":0.044696,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.085332,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790323200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1666238400000,"exchange":"NASDAQ","adjPreClose":3.13,"preHourTrading":{"tag":"盘前","latestPrice":3.11,"preClose":3.13,"latestTime":"09:21 EDT","volume":15178,"amount":47230.778976,"timestamp":1790256102975,"change":-0.02,"changeRate":-0.00639,"amplitude":0.009585},"postHourTrading":{"tag":"盘后","latestPrice":3.4301,"preClose":3.07,"latestTime":"19:59 EDT","volume":1896151,"amount":6531260.1016,"timestamp":1790294399645,"change":0.3601,"changeRate":0.117296,"amplitude":0.172638},"volumeRatio":1.324484,"impliedVol":1.1935,"impliedVolPercentile":0.7171},"requestUrl":"/m/hq/s/PRME","defaultTab":"news","newsList":[{"id":"2670412701","title":"Chardan Capital Sticks to Their Buy Rating for Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670412701","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670412701?lang=en_us&edition=fundamental","pubTime":"2026-09-25 11:35","pubTimestamp":1790307314,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst Keay Nakae maintained a Buy rating on Prime Medicine, Inc. yesterday and set a price target of $7.00. According to TipRanks...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670726415","title":"Stocks to Watch: Akamai, Scholastic, Prime Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2670726415","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670726415?lang=en_us&edition=fundamental","pubTime":"2026-09-25 06:46","pubTimestamp":1790289960,"startTime":"0","endTime":"0","summary":"Akamai Technologies struck an $11.6 billion deal with Anthropic for its computing services. Shares rallied 22% to $134.88 in after-hours trading Thursday.Scholastic logged lower sales in its first fis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKAM","AKAL","LU2286300806.USD","BK4139","BK4588","BK4554","SCHL","BK4111","BK4585","BK4116","LU1059921491.USD","PRME","BK4608"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670151394","title":"Analysts Are Bullish on Top Healthcare Stocks: Arcus Biosciences (RCUS), Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670151394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670151394?lang=en_us&edition=fundamental","pubTime":"2026-09-25 05:50","pubTimestamp":1790286610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcus Biosciences (RCUS) and Prime Medicine, Inc. (P...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-arcus-biosciences-rcus-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-arcus-biosciences-rcus-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RCUS","LABU","LU0029874061.USD","BK4581","XBI","HCSG","BK4139","BK4585","PRME","BK4588","LU0128526141.USD","BK4137","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670139964","title":"Prime Medicine Shares Jump on FDA Clearance for Investigational New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2670139964","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670139964?lang=en_us&edition=fundamental","pubTime":"2026-09-25 05:08","pubTimestamp":1790284080,"startTime":"0","endTime":"0","summary":"Shares of Prime Medicine jumped after the biotechnology company said the Food and Drug Administration cleared its investigational new drug application for PM647 to treat the genetic disease Alpha-1 Antitrypsin Deficiency.Shares were up 13% to $3.47 in after-hours trading on Thursday after closing down 1.9% at $3.07. Through the close, the stock had fallen 12% this year.The company said the FDA's clearance means it can initiate clinical studies in the U.S.\"FDA clearance of the PM647 IND is an important milestone for Prime Medicine, marking continued momentum across our liver franchise,\" Chief Executive Officer Allan Reine said. \"PM647 has the potential to change how AATD is treated, offering a Prime Editing-based approach that moves beyond protein replacement and targets the root cause of disease.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4585","BK4588","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670629418","title":"Prime Medicine announces FDA clearance of IND application for PM647","url":"https://stock-news.laohu8.com/highlight/detail?id=2670629418","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670629418?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:05","pubTimestamp":1790280337,"startTime":"0","endTime":"0","summary":"Prime Medicine (PRME) announced that the FDA has cleared the company’s Investigational New Drug, or IND, application for PM647, an investigational ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/prime-medicine-announces-fda-clearance-of-ind-application-for-pm647-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/prime-medicine-announces-fda-clearance-of-ind-application-for-pm647-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","BK4139","BK4588","PRME","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670549005","title":"Prime Medicine Wins FDA IND Clearance for PM647 in Alpha-1 Antitrypsin Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2670549005","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670549005?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:01","pubTimestamp":1790280081,"startTime":"0","endTime":"0","summary":"Prime Medicine wins FDA IND clearance for PM647 in alpha-1 antitrypsin deficiencyPrime Medicine secured FDA clearance for an IND for PM647, an in vivo prime editor for alpha-1 antitrypsin deficiency.C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nNDL5tThl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00BN0W2V16.EUR","BK4588","SG9999014021.USD","IE00BQXX3F31.USD","IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","LU2095319765.USD","PRME","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4139","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670749070","title":"Prime Medicine, - Initial Clinical Data for Pm647 Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2670749070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670749070?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:01","pubTimestamp":1790280060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA3ZFFJ5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670549070","title":"Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for Pm647 in Alpha-1 Antitrypsin Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2670549070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670549070?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:01","pubTimestamp":1790280060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA3ZFFJ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664871296","title":"Prime Medicine Set for Fireside Chats at H.C. Wainwright, Morgan Stanley Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871296","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664871296?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:02","pubTimestamp":1788436978,"startTime":"0","endTime":"0","summary":"Prime Medicine set for fireside chats at H.C. Wainwright, Morgan Stanley healthcare conferencesPrime Medicine management schedules investor meetings at the Wells Fargo 21st Annual Healthcare Conferenc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL7XkcrQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225283273.USD","IAI","LU1074936037.SGD","LU1244550221.USD","LU1548497426.USD","LU2089284900.SGD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","NDAQ","LU0158827948.USD","LU0106831901.USD","LU1668664300.SGD","LU0210528500.USD","LU1988902786.USD","IE00BQXX3D17.EUR","LU0098860793.USD","LU1720051017.SGD","LU1791710400.SGD","KBWB","SG9999014039.USD","LU1244550494.USD","IE00BGHQF748.EUR","BK4139","IE00BN0W2W23.USD","LU1791710582.SGD","LU0557290698.USD","LU0053666078.USD","LU1732800096.USD","LU0390134368.USD","LU2023251221.USD","IE00BQXX3C00.GBP","BK4581","LU2028103732.USD","IE00BZ1G4Q59.USD","LU2264538146.SGD","LU1363072403.SGD","PRME","LU1720051108.HKD","LU0795875169.SGD","IE00BQXX3F31.USD","LU1064131342.USD","LU0882574139.USD","LU2210150020.SGD","SG9999014021.USD","LU2095319765.USD","LU0314104364.USD","LU0912757837.SGD","LU2111349929.HKD","LU2133065610.SGD","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662734464","title":"Prime Medicine Price Target Maintained with a $7.00/Share by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2662734464","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662734464?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:15","pubTimestamp":1787660100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662784346","title":"Chardan Capital Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662784346","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662784346?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:25","pubTimestamp":1787642725,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst Keay Nakae maintained a Buy rating on Prime Medicine, Inc. today and set a price target of $7.00. According to TipRanks, Na...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-reaffirms-their-buy-rating-on-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-reaffirms-their-buy-rating-on-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658075987","title":"Prime Medicine Price Target Maintained with a $8.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2658075987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658075987?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:35","pubTimestamp":1786358100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661357","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Cresco Labs (OtherCRLBF), Prime Medicine, Inc. (PRME) and Steris (STE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661357?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:30","pubTimestamp":1786055431,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cresco Labs (CRLBF), Prime Medicine, Inc. (PRME) and Steris (STE)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cresco-labs-othercrlbf-prime-medicine-inc-prme-and-steris-ste-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cresco-labs-othercrlbf-prime-medicine-inc-prme-and-steris-ste-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU0289961442.SGD","XBI","PRME","BK4588","HCSG","LU1892829315.USD","LU0128526141.USD","BK4581","LABU","BK4585","XLV","BK4139","LU0057025933.USD","LU0069063385.USD","LU0511384066.AUD","LU0124676726.USD","STE","LU0472753341.HKD","BK4137","LU0289739343.SGD","CRLBF","BK4082","LU0029874061.USD","LU0689626769.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657965099","title":"NextCure Q2 Net Loss Narrows on Lower Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657965099","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657965099?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:16","pubTimestamp":1786047402,"startTime":"0","endTime":"0","summary":"NextCure Q2 net loss narrows on lower expensesOverviewU.S. cancer drug developer's Q2 net loss narrowed yr/yr on lower R&D and admin costsCompany announced proposed merger with Avere Therapeutics, exp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139","ALXO","NXTC","TRDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657665749","title":"INmune Bio Q2 Net Loss Narrows on Lower Impairment Charges","url":"https://stock-news.laohu8.com/highlight/detail?id=2657665749","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657665749?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:09","pubTimestamp":1786046981,"startTime":"0","endTime":"0","summary":"INmune Bio Q2 net loss narrows on lower impairment chargesOverviewUS biotechnology firm's Q2 net loss narrowed sharply from prior yearCompany reported no revenue for the quarterQ2 results benefited fr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INMB","PRME","ALXO","EBS","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657658045","title":"Prime Medicine, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657658045","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657658045?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:07","pubTimestamp":1786028851,"startTime":"0","endTime":"0","summary":"Prime Medicine, Inc. reports results for the quarter ended June 30 - Earnings SummaryPrime Medicine, Inc.PRME.OQreported a quarterly adjusted loss of 24 cents per share for the quarter ended June 30, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4432HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639105","title":"Prime Medicine Publishes Corporate Presentation on Prime Editing Platform, Liver Disease Pipeline Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639105","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639105?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:20","pubTimestamp":1786018846,"startTime":"0","endTime":"0","summary":"Prime Medicine publishes corporate presentation on prime editing platform, liver disease pipeline focusPrime Medicine highlighted a near-term focus on in vivo liver programs, led by Wilson disease can","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLbrmPs0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639522","title":"Prime Medicine, Inc. Q2 EPS USD -0.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639522","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639522?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:13","pubTimestamp":1786018417,"startTime":"0","endTime":"0","summary":"Aug 06 (Reuters) - Prime Medicine, Inc. Q2 operating expenses USD 44.439 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 06-AUG-202612:01:02.427 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nRSDw0yDt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657367546","title":"Prime Medicine Q2 FY26 Net Loss Narrows to $42.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657367546","media":"Reuters","labels":["policyRegulatory","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657367546?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:04","pubTimestamp":1786017850,"startTime":"0","endTime":"0","summary":"Prime Medicine Q2 FY26 net loss narrows to $42.1 millionPrime Medicine posted a net loss of USD 42.1 million for Q2 2026, narrowing from USD 52.6 million a year earlier.R&D expense fell 19.32% to USD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL7VRXWs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657947636","title":"Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657947636","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657947636?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:01","pubTimestamp":1786017719,"startTime":"0","endTime":"0","summary":"Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 41.46 percent increase over losses of $(0.41) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60991240/prime-medicine-q2-eps-0-24-beats-0-26-estimate-sales-1-154m-miss-1-295m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.primemedicine.com;investors.primemedicine.com","stockEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.1725},{"period":"3month","weight":-0.105},{"period":"6month","weight":-0.0917},{"period":"1year","weight":-0.4478},{"period":"ytd","weight":-0.1153}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.2099},{"period":"1year","weight":0.1605},{"period":"ytd","weight":0.125}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070058},{"month":2,"riseRate":0.5,"avgChangeRate":0.101559},{"month":3,"riseRate":0,"avgChangeRate":-0.224329},{"month":4,"riseRate":0.5,"avgChangeRate":-0.072402},{"month":5,"riseRate":0.5,"avgChangeRate":-0.000767},{"month":6,"riseRate":0.75,"avgChangeRate":0.248413},{"month":7,"riseRate":0.75,"avgChangeRate":0.106402},{"month":8,"riseRate":0.25,"avgChangeRate":-0.065687},{"month":9,"riseRate":0.25,"avgChangeRate":0.047445},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.141809},{"month":11,"riseRate":0.25,"avgChangeRate":-0.086687},{"month":12,"riseRate":0.5,"avgChangeRate":0.02429}],"exchange":"NASDAQ","name":"Prime Medicine, Inc.","nameEN":"Prime Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Prime Medicine, Inc.,PRME,Prime Medicine, Inc.股票,Prime Medicine, Inc.股票老虎,Prime Medicine, Inc.股票老虎国际,Prime Medicine, Inc.行情,Prime Medicine, Inc.股票行情,Prime Medicine, Inc.股价,Prime Medicine, Inc.股市,Prime Medicine, Inc.股票价格,Prime Medicine, Inc.股票交易,Prime Medicine, Inc.股票购买,Prime Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction